| Entry |
|
|---|
| Symbol |
CASP8, ALPS2B, CAP4, Casp-8, FLICE, MACH, MCH5
|
|---|
| Name |
|
|---|
| KO |
|
|---|
| Organism |
|
|---|
| Pathway |
| hsa04620 | Toll-like receptor signaling pathway |
| hsa04621 | NOD-like receptor signaling pathway |
| hsa04622 | RIG-I-like receptor signaling pathway |
| hsa04625 | C-type lectin receptor signaling pathway |
| hsa04932 | Non-alcoholic fatty liver disease |
| hsa05022 | Pathways of neurodegeneration - multiple diseases |
| hsa05130 | Pathogenic Escherichia coli infection |
| hsa05163 | Human cytomegalovirus infection |
| hsa05167 | Kaposi sarcoma-associated herpesvirus infection |
| hsa05168 | Herpes simplex virus 1 infection |
| hsa05170 | Human immunodeficiency virus 1 infection |
|
|---|
| Network |
|
|---|
| Element |
| N00145 | Extrinsic apoptotic pathway |
| N00146 | Crosstalk between extrinsic and intrinsic apoptotic pathways |
| N00166 | KSHV vFLIP to crosstalk between extrinsic and intrinsic apoptotic pathways |
| N00352 | HPV E6 to extrinsic apoptotic pathway |
| N00425 | HCMV UL36 to crosstalk between extrinsic and intrinsic apoptotic pathways |
| N00449 | HIV Tat/Nef to crosstalk between extrinsic and intrinsic apoptotic pathways |
| N00526 | HCV NS3 to crosstalk between extrinsic and intrinsic apoptotic pathways |
| N00528 | HCV core to extrinsic apoptotic pathway |
| N00579 | HSV ICP6 to extrinsic apoptotic pathway |
| N00937 | Escherichia NleF to extrinsic apoptotic pathway |
| N00983 | Mutation-caused aberrant Htt to extrinsic apoptotic pathway |
| N01005 | Mutation-caused aberrant Abeta to crosstalk between extrinsic and intrinsic apoptotic pathways |
| N01583 | Regulation of extrinsic apoptotic pathway, XIAP |
| N01663 | CASP8 regulation of RIPK1/3 |
|
|---|
| Disease |
| H00048 | Hepatocellular carcinoma |
| H00108 | Autoimmune lymphoproliferative syndromes |
|
|---|
| Brite |
KEGG Orthology (KO) [BR:hsa00001]
09130 Environmental Information Processing
09132 Signal transduction
04668 TNF signaling pathway
841 (CASP8)
09140 Cellular Processes
09143 Cell growth and death
04215 Apoptosis - multiple species
841 (CASP8)
09150 Organismal Systems
09151 Immune system
04620 Toll-like receptor signaling pathway
841 (CASP8)
04657 IL-17 signaling pathway
841 (CASP8)
09160 Human Diseases
09161 Cancer: overview
05200 Pathways in cancer
841 (CASP8)
05203 Viral carcinogenesis
841 (CASP8)
09172 Infectious disease: viral
05170 Human immunodeficiency virus 1 infection
841 (CASP8)
05161 Hepatitis B
841 (CASP8)
05160 Hepatitis C
841 (CASP8)
05164 Influenza A
841 (CASP8)
05162 Measles
841 (CASP8)
05163 Human cytomegalovirus infection
841 (CASP8)
05167 Kaposi sarcoma-associated herpesvirus infection
841 (CASP8)
05169 Epstein-Barr virus infection
841 (CASP8)
05165 Human papillomavirus infection
841 (CASP8)
09171 Infectious disease: bacterial
05130 Pathogenic Escherichia coli infection
841 (CASP8)
05134 Legionellosis
841 (CASP8)
05152 Tuberculosis
841 (CASP8)
09174 Infectious disease: parasitic
05145 Toxoplasmosis
841 (CASP8)
05142 Chagas disease
841 (CASP8)
09164 Neurodegenerative disease
05010 Alzheimer disease
841 (CASP8)
05016 Huntington disease
841 (CASP8)
05022 Pathways of neurodegeneration - multiple diseases
841 (CASP8)
09166 Cardiovascular disease
05417 Lipid and atherosclerosis
841 (CASP8)
05416 Viral myocarditis
841 (CASP8)
09167 Endocrine and metabolic disease
04936 Alcoholic liver disease
841 (CASP8)
04932 Non-alcoholic fatty liver disease
841 (CASP8)
09176 Drug resistance: antineoplastic
01524 Platinum drug resistance
841 (CASP8)
09180 Brite Hierarchies
09181 Protein families: metabolism
01002 Peptidases and inhibitors [BR:hsa01002]
841 (CASP8)
Enzymes [BR:hsa01000]
3. Hydrolases
3.4 Acting on peptide bonds (peptidases)
3.4.22 Cysteine endopeptidases
3.4.22.61 caspase-8
841 (CASP8)
Peptidases and inhibitors [BR:hsa01002]
Cysteine peptidases
Family C14: caspase family
841 (CASP8)
|
|---|
| SSDB |
|
|---|
| Motif |
|
|---|
| Other DBs |
|
|---|
| Structure |
|
|---|
| LinkDB |
|
|---|
| Position |
2:201233463..201287711
|
|---|
| AA seq |
479 aa
MDFSRNLYDIGEQLDSEDLASLKFLSLDYIPQRKQEPIKDALMLFQRLQEKRMLEESNLS
FLKELLFRINRLDLLITYLNTRKEEMERELQTPGRAQISAYRVMLYQISEEVSRSELRSF
KFLLQEEISKCKLDDDMNLLDIFIEMEKRVILGEGKLDILKRVCAQINKSLLKIINDYEE
FSKERSSSLEGSPDEFSNGEELCGVMTISDSPREQDSESQTLDKVYQMKSKPRGYCLIIN
NHNFAKAREKVPKLHSIRDRNGTHLDAGALTTTFEELHFEIKPHDDCTVEQIYEILKIYQ
LMDHSNMDCFICCILSHGDKGIIYGTDGQEAPIYELTSQFTGLKCPSLAGKPKVFFIQAC
QGDNYQKGIPVETDSEEQPYLEMDLSSPQTRYIPDEADFLLGMATVNNCVSYRNPAEGTW
YIQSLCQSLRERCPRGDDILTILTEVNYEVSNKDDKKNMGKQMPQPTFTLRKKLVFPSD |
|---|
| NT seq |
1440 nt +upstreamnt +downstreamnt
atggacttcagcagaaatctttatgatattggggaacaactggacagtgaagatctggcc
tccctcaagttcctgagcctggactacattccgcaaaggaagcaagaacccatcaaggat
gccttgatgttattccagagactccaggaaaagagaatgttggaggaaagcaatctgtcc
ttcctgaaggagctgctcttccgaattaatagactggatttgctgattacctacctaaac
actagaaaggaggagatggaaagggaacttcagacaccaggcagggctcaaatttctgcc
tacagggtcatgctctatcagatttcagaagaagtgagcagatcagaattgaggtctttt
aagtttcttttgcaagaggaaatctccaaatgcaaactggatgatgacatgaacctgctg
gatattttcatagagatggagaagagggtcatcctgggagaaggaaagttggacatcctg
aaaagagtctgtgcccaaatcaacaagagcctgctgaagataatcaacgactatgaagaa
ttcagcaaagagagaagcagcagccttgaaggaagtcctgatgaattttcaaatggggag
gagttgtgtggggtaatgacaatctcggactctccaagagaacaggatagtgaatcacag
actttggacaaagtttaccaaatgaaaagcaaacctcggggatactgtctgatcatcaac
aatcacaattttgcaaaagcacgggagaaagtgcccaaacttcacagcattagggacagg
aatggaacacacttggatgcaggggctttgaccacgacctttgaagagcttcattttgag
atcaagccccacgatgactgcacagtagagcaaatctatgagattttgaaaatctaccaa
ctcatggaccacagtaacatggactgcttcatctgctgtatcctctcccatggagacaag
ggcatcatctatggcactgatggacaggaggcccccatctatgagctgacatctcagttc
actggtttgaagtgcccttcccttgctggaaaacccaaagtgttttttattcaggcttgt
cagggggataactaccagaaaggtatacctgttgagactgattcagaggagcaaccctat
ttagaaatggatttatcatcacctcaaacgagatatatcccggatgaggctgactttctg
ctggggatggccactgtgaataactgtgtttcctaccgaaaccctgcagagggaacctgg
tacatccagtcactttgccagagcctgagagagcgatgtcctcgaggcgatgatattctc
accatcctgactgaagtgaactatgaagtaagcaacaaggatgacaagaaaaacatgggg
aaacagatgcctcagcctactttcacactaagaaaaaaacttgtcttcccttctgattga |
|---|
